BCLSI
AMLX icon

Bain Capital Life Sciences Investors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,023,214
Closed -$28.8M – 34
2022
Q3 		$28.8M Sell
1,023,214
-925,000
-47% -$23.1M 3.44% 9
2022
Q2 		$37.5M Sell
1,948,214
-807,836
-29% -$9.59M 4.4% 9
2022
Q1 		$35.4M Buy
+2,756,050
New +$62.2M 3.44% 10

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bain Capital Life Sciences Investors's AMLX Position: Q4 2022 in Review

Bain Capital Life Sciences Investors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2022, closing a stake of 1,023,214 shares — an estimated $28.8M sold.

Bain Capital Life Sciences Investors first reported a position in AMLX in Q1 2022 and held it in 3 quarters. The position peaked at $37.5M in Q2 2022. 133 funds tracked by Wall St. Rank hold AMLX as of Q4 2022.

  • Bain Capital Life Sciences Investors reported no remaining Amylyx Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 1,023,214 Amylyx Pharmaceuticals shares in Q4 2022, an estimated $28.8M.
  • Bain Capital Life Sciences Investors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Bain Capital Life Sciences Investors's Amylyx Pharmaceuticals position peaked at $37.5M in Q2 2022.
  • 133 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2022, filed 14 Feb 2023.